Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. (Operator Instructions) I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...

(NYSE: AGL), the trusted partner empowering physicians to transform health in our communities, announced that it will release its financial results for the fourth quarter and full year 2024 after the ...

Brixmor Property Group Inc. ("Brixmor" or the "Company") announced today its operating results for the three and twelve months ended December 31, 2024.  For the three months ended December 31, 2024 ...

During the recent period, Arrowhead (ARWR) signed and closed a potentially transformational licensing and collaboration agreement with Sarepta ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now ...

This article is a text version of a Wall Street Journal newsletter published earlier today.

Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...